Blau Farmacêutica S.A.

BOVESPA:BLAU3 Stock Report

Market Cap: R$2.3b

Blau Farmacêutica Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Marcelo Hahn

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownership83.3%
Management average tenureless than a year
Board average tenureno data

Recent management updates

Recent updates

Does Blau Farmacêutica (BVMF:BLAU3) Have A Healthy Balance Sheet?

Dec 04
Does Blau Farmacêutica (BVMF:BLAU3) Have A Healthy Balance Sheet?

Results: Blau Farmacêutica S.A. Exceeded Expectations And The Consensus Has Updated Its Estimates

Nov 07
Results: Blau Farmacêutica S.A. Exceeded Expectations And The Consensus Has Updated Its Estimates

Blau Farmacêutica S.A.'s (BVMF:BLAU3) 25% Share Price Surge Not Quite Adding Up

Nov 06
Blau Farmacêutica S.A.'s (BVMF:BLAU3) 25% Share Price Surge Not Quite Adding Up

Blau Farmacêutica S.A.'s (BVMF:BLAU3) 31% Price Boost Is Out Of Tune With Earnings

Aug 29
Blau Farmacêutica S.A.'s (BVMF:BLAU3) 31% Price Boost Is Out Of Tune With Earnings

Is Blau Farmacêutica (BVMF:BLAU3) A Risky Investment?

Jun 28
Is Blau Farmacêutica (BVMF:BLAU3) A Risky Investment?

Lacklustre Performance Is Driving Blau Farmacêutica S.A.'s (BVMF:BLAU3) 26% Price Drop

Feb 01
Lacklustre Performance Is Driving Blau Farmacêutica S.A.'s (BVMF:BLAU3) 26% Price Drop

What Does The Future Hold For Blau Farmacêutica S.A. (BVMF:BLAU3)? These Analysts Have Been Cutting Their Estimates

May 14
What Does The Future Hold For Blau Farmacêutica S.A. (BVMF:BLAU3)? These Analysts Have Been Cutting Their Estimates

Blau Farmacêutica S.A. Just Missed EPS By 18%: Here's What Analysts Think Will Happen Next

Feb 24
Blau Farmacêutica S.A. Just Missed EPS By 18%: Here's What Analysts Think Will Happen Next

Getting In Cheap On Blau Farmacêutica S.A. (BVMF:BLAU3) Is Unlikely

Oct 14
Getting In Cheap On Blau Farmacêutica S.A. (BVMF:BLAU3) Is Unlikely

Robust Earnings May Not Tell The Whole Story For Blau Farmacêutica (BVMF:BLAU3)

Aug 17
Robust Earnings May Not Tell The Whole Story For Blau Farmacêutica (BVMF:BLAU3)

CEO

Marcelo Hahn

no data

Tenure

Mr. Marcelo Rodolfo Hahn is the Founder and serves as Controller & Chief Executive Officer at Blau Farmacêutica S/A and serves as its Deputy Chairman of the Board. Mr. Hahn served as President at Blau Farm...

Leadership Team

NamePositionTenureCompensationOwnership
Marcelo Hahn
Founderno datano data83.3%
R$ 1.9b
Douglas Rodrigues
CFO & Investor Relations Officer3yrsno datano data
Vanderlei Schiavo
Chief Technologyless than a yearno datano data
Roberto Altieri
Chief Legal Officerno datano datano data
Ana Luzia Ivanov
Chief Peopleless than a yearno datano data
Roberto Carlos de Morais
Chief M&A and Operations (USA and Europe) Officer & Directorless than a yearno datano data
Eliza Saito
Chief Quality Officerless than a yearno datano data
Eliana Sueco Samano
Chief Medical Officerless than a yearno datano data
Amaro de Souza Junior
Chief Business Unit Officer of Onco-Hematology and Specialtiesless than a yearno datano data
Milton Rizo
Chief Industrial Operations Officerless than a yearno datano data
Uilberson da Silva
Chief Researchless than a yearno datano data
Erica Maluf
Chief Regulatory Affairs Officerless than a yearno datano data

0.3yrs

Average Tenure

Experienced Management: BLAU3's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 02:01
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Blau Farmacêutica S.A. is covered by 13 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Marcio OsakoBradesco S.A. Corretora de Títulos e Valores Mobiliários
Frederico MendesBradesco S.A. Corretora de Títulos e Valores Mobiliários
Samuel Campos AlvesBTG Pactual